← Corcept Therapeutics Incorporated (CORT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Corcept Therapeutics Incorporated (CORT)
Pharmaceutical Preparations · market cap $12.5B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
14
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Corcept Therapeutics (CORT) is a ~$10B market cap commercial-stage pharmaceutical company focused on cortisol modulation, generating $761M in revenue in 2025 from its marketed mifepristone franchise. The company carries a deep pipeline of selective glucocorticoid receptor antagonists across oncology, psychiatry, and metabolic disease, with two near-term Phase 2 readouts in ovarian cancer (relacorilant) and ALS (dazucorilant) expected in Q3-Q4 2026.
The catalyst path
- 2026-10-15 (est.)Phase 2 · Dazucorilant 300 mgimp 7/10
- 2026-11-03 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 2 · Gemcitabine 1000 mg/m^2imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| mifepristone 600 mg | Phase 3 | Major Depressive Disorder |
| CORT125281 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer |
| Mifepristone | Phase 3 | Depressive Disorder, Major |
| Relacorilant 150 mg once daily (QD) | Phase 3 | Ovarian Cancer |
| Miricorilant | Phase 2 | Antipsychotic-induced Weight Gain (AIWG) |
| CORT125134 | Phase 2 | Cushing's Syndrome |
| Miricorilant (Cohort A) | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| Miricorlilant | Phase 2 | Antipsychotic-induced Weight Gain (AIWG) |
| Nab-paclitaxel 100 mg/m^2 | Phase 3 | Ovarian Neoplasm |
| Dazucorilant 300 mg | Phase 2 | Amyotrophic Lateral Sclerosis |
| Relacorilant with nab-paclitaxel | Phase 2 | Solid Tumors |
| Nenocorilant 200 mg | Phase 2 | Neoplasms |
| Relacorilant | Phase 3 | Recurrent Ovarian Cancer |
| Gemcitabine 1000 mg/m^2 | Phase 2 | Adenocarcinoma |
Price & technical context
3-month
+26.4%
6-month
+171.6%
12-month
+35.3%
52-wk range
$32.15–$123.57
vs 50-day MA
+1.3%
vs 200-day MA
+63.4%
Realized vol
95.1%
Max drawdown
-71.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CORT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.